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Abstract
Hemophilia remains a non-curative disease,and patients are constrained to
undergo repeated injections of clotting factors. In contrast, the sustained
production of endogenous factors VIII (FVIII) or IX (FIX)by the patient’s own cells
could represent a curative treatment. Gene therapy has thus provided new hope
for these patients. However, the issues surrounding the durability of expression
and immune responses against gene transfer vectors remain. Cell therapy,
involving stem cells expanded in vitro, can provide de novo protein synthesis and,
if implanted successfully, could induce a steady-state production of low quantities
of factors, which may keep the patient above the level required to prevent
spontaneous bleeding. Liver-derived stem cells are already being assessed in
clinical trials for inborn errors of metabolism and, in view of their capacity to
produce FVIII and FIX in cell culture, they are now also being considered for
clinical application in hemophilia patients.
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Summary. Hemophilia remains a non-curative disease,
and patients are constrained to undergo repeated injec-
tions of clotting factors. In contrast, the sustained pro-
duction of endogenous factors VIII (FVIII) or IX (FIX)
by the patient’s own cells could represent a curative treat-
ment. Gene therapy has thus provided new hope for these
patients. However, the issues surrounding the durability
of expression and immune responses against gene transfer
vectors remain. Cell therapy, involving stem cells
expanded in vitro, can provide de novo protein synthesis
and, if implanted successfully, could induce a steady-state
production of low quantities of factors, which may keep
the patient above the level required to prevent spontane-
ous bleeding. Liver-derived stem cells are already being
assessed in clinical trials for inborn errors of metabolism
and, in view of their capacity to produce FVIII and FIX
in cell culture, they are now also being considered for
clinical application in hemophilia patients.
Keywords: exosomes; hemophilia A; liver; metabolism,
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Introduction
Hemophilia A is the most common severe inherited bleed-
ing disorder, affecting 1 in 5000 male births. This pathol-
ogy exhibits different phenotypic expressions depending
on its associated factor VIII (FVIII) plasma levels, result-
ing in severe (< 1%), moderate (1–5%), or mild (6–30%)
forms of expression [1]. This disease originates from an
inherited deficiency or dysfunction in the procoagulant
FVIII, a crucial element of the intrinsic pathway of blood
coagulation involved in the conversion of factor X to Xa
[2]. In severe cases, FVIII deficiency leads to spontaneous
bleeding and internal hemorrhage that can cause disabil-
ity and even death, if left untreated [3].
There is currently no cure for hemophilia A. The ratio-
nale behind replacement treatment is to sufficiently
increase concentrations of the missing factor to arrest
spontaneous and traumatic bleeds. Plasma-derived prod-
ucts became available in the 1970s, proving effective in
controlling bleeding episodes through the development of
home-therapy programs. However, concentrates derived
from pooled plasma were contaminated with HIV and
the hepatitis B or C virus, causing post-transfusion hepa-
titis and immunodeficiency in almost all hemophilia
patients who received these concentrates. In 1984, the
FVIII gene was successfully cloned, enabling the produc-
tion of recombinant human FVIII (rFVIII) using mam-
malian cell cultures, and the first rFVIII went on the
market in 1992 [4].
The introduction of rFVIII revolutionized hemophilia
patient management by providing an effective and safe
treatment of bleeding episodes. Nevertheless, there remain
several issues concerning FVIII replacement therapy that
have yet to be resolved. The primary complications are as
follows: the short half-life of replacement products, neces-
sitating frequent intravenous infusions; the immunogenic-
ity of FVIII concentrates; and the affordability and
availability of FVIII products [5].
During the last decades, several attempts have been
made to develop a long-term ‘cure’, such as gene and cell
therapy. Hemophilia A is a perfect candidate for gene
therapy, given its monogenetic nature that can potentially
be cured by continuous endogenous FVIII expression.
For hemophilia treatment, by increasing circulating clot-
ting factor levels to above 1% of normal, it may be possi-
ble to obtain a prophylactic therapeutic effect, thereby
reducing risks of both mortality and morbidity.
If gene therapy is able to slightly increase clotting
factor levels, it could significantly improve the clinical
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phenotype [6]. Recently, hemophilia B gene therapy has
achieved promising outcomes in human clinical trials [7].
A key advantage of the development of gene therapy
strategies for hemophilia B is the relatively small size of
the cDNA of FIX, measuring approximately 1.4 kB of
the coding sequence. This renders it amenable to insertion
into different gene transfer vectors and enables the addi-
tion of numerous transcriptional regulatory elements to
both improve and restrict transgene expression in selected
cell types. The cDNA of FVIII is much larger than that
of FIX (> 8 kB) and cannot be as readily accommodated
in gene transfer vectors. Several strategies have previously
been attempted to overcome this difficulty, by either
deleting the B-domain or using two viral vectors [8].
Moreover, the main complication of viral vector delivery
of clotting factor transgenes is the host immune responses
[9]. A pre-existing immune response against capsid proteins
is one of the criteria excluding hemophilia patients from
gene therapy. Approximately 40% of the adult human pop-
ulation possess neutralizing antibodies against the adeno-
associated virus (AAV)-2 [10], and these antibodies can
cross-neutralize other AAV serotypes. In addition, patients
receiving systemic viral vector administration develop a
postgene therapy immune response. This response was
shown to be associated with the destruction of cells express-
ing viral proteins after transduction, thereby decreasing the
gene transfer’s efficacy, along with the development of neu-
tralizing antibodies against the viral vector employed as
therapeutic agent, therefore preventing the possibility of
vector re-administration.
Orthotopic liver transplantation has proven effective in
correcting the hemophilic phenotype in hemophilia
patients with decompensated hepatitis C (HCV)-cirrhosis
[11]. This suggests that the liver plays a central role in
producing blood-clotting factors like FVIII. The hepatic
cellular compartments that produce FVIII are primarily
composed of liver sinusoidal endothelial cells (LSEC)
[12,13], although earlier evidence has suggested hepato-
cytes to be instrumental in FVIII expression [14]. Trans-
planting such cells that are capable of releasing FVIII
in situ or into the circulation is an attractive approach for
treating clotting factor disorders. Notably, in murine
endothelial cell cultures, FVIII production was measured
to amount to 0.07 IU million1 cells day1. If we extrap-
olate this to the 8 9 1010 liver endothelial cells contained
in an adult human liver, the production would cover
more than that required by a human adult [15]. Trans-
planting 2 9 106 mature LSECs, representing 10% of
their endothelial compartment, via the portal vein in
hemophilia A mice was shown to restore plasma FVIII
activity levels to 14%–25% of normal, thereby correcting
spontaneous bleeding [16].
In addition to endothelial cells, mesenchymal stem cells
(MSCs) are also able to secrete FVIII in the cell culture
supernatant, which makes them attractive candidates for
treating hemophilia. MSCs are increasingly used in sev-
eral medical areas for repairing organs, such as the heart,
bone, cartilage, and liver. These are tissue-resident cells
that can be obtained from different tissues and organs,
exhibiting the propensity to attach onto surfaces and pro-
liferate in vitro. In certain conditions, they differentiate
into mature cells, such as bone, cartilage, and adipocyte-
or hepatocyte-like cells. These cells express specific surface
markers, such as CD90 and CD105, and are negative for
hematopoietic markers like CD45 [17]. However, MSC
from different tissues may differ by other characteristics.
For example, unmodified MSCs from human liver and
lungs produce FVIII in the culture supernatant in much
higher quantities compared to human bone marrow-
derived MSCs (1.2 and 1.7% vs. 0.12%, respectively, per
105 cells at the 48-h time point) [18].
We similarly tested by chonometric assay factor VIII
production in the supernatant of human-derived mesench-
ymal cells [19], cultured in large-scale in accordance with
good manufacturing practices (GMP), produced FVIII
measured by chronometric assay in the culture supernatant.
(G. Rommelaere, S. Eeckhoudt, C. Lombard, E. Sokal,
unpublished data). FVIII levels, accumulated over time,
suggesting that the production exceeded degradation,
despite the absence of stabilizing von Willebrand factor.
This accumulation has been attributed to the fact that these
cells do not store FVIII in granules while secreting most of
the produced protein [18].
In animal experiments, sheep bone marrow MSCs
transduced with porcine FVIII vector were shown to be
effective in mitigating joint bleeding following peritoneal
transplantation in sheep affected by hemophilia A. The
transplanted cells were observed homing to the joints,
locally expressing FVIII [20]. Similar results were found
in mice, where intra-articular injections of autologous
MSCs overexpressing FVIII had a positive impact on
hemarthrosis and arthropathy associated with bleeding
challenges [21]. In another experiment, injecting bone
marrow (BM)-macrophages or BM-mesenchymal stromal
cells protected hemophilia A mice from bleeding chal-
lenges after 3 days, with FVIII manifesting in the blood
[16]. The effect was attributed to bone marrow mononu-
clear cells and MSCs, given that no donor bone marrow-
derived endothelial cells or parenchymal cells were found
in these animals.
Extracellular vesicles produced by stem cells
When stem cells are transplanted, a complex interrelation-
ship very likely exists between the contribution of the
direct engraftment of the cell at the site of the expected
regeneration and the role of the ‘material’ released by the
cells required for mediating engraftment, differentiation,
phenotype changes, immunological response, apoptosis,
and so on. This type of released material includes not
only soluble molecules, such as growth factors, but also
extracellular vesicles naturally secreted by the cells. Extra-
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cellular vesicles are produced by most eukaryotic cells,
including stem cells [22–26]. Although both terms are at
times used interchangeably, microparticles (MPs) differ
from exosomes on account of their size, content, and the
way they are formed. MPs range from 100 to 1000 nm in
size and are shed from the cell’s plasma membrane as a
result of cellular stress. They are enriched in molecules,
such as cholesterol, integrins, and flotillins. Exosomes are
membranous vesicles ranging from 30 to 100 nm in size
and released following the fusion of multivesicular bodies
with the plasma membrane. They are enriched in
heat-shock proteins, tetraspanins, and endosome-specific
proteins, such as Alix and TSG101. Both types of extra-
cellular vesicles also contain deoxyribonucleic acid
(DNA), ribonucleic acid (RNA), and micro-RNA (miR-
NA) [22–26]. This cargo of proteins, lipids, and genetic
material is readily transferrable from one cell to another,
even between very remote cells, and can influence the phe-
notype and fate of target cells in transplantation [27]. The
genetic material released by the donor cells enters the host
cells and either modulates the expression of endogenous
genes, as is the case with miRNAs, or is expressed and
can contribute to the restoration of an impaired cell func-
tion, as with mRNAs [22–26]. For example, exosomes
released from MSCs have been found to mediate, at least
in part, the observed regenerative effects of applied MSCs
in the context of cardiac tissue repair [28]. Similarly, the
experimental and clinical use of MSCs and liver stem cells
in the setting of alcoholic liver disorders has highlighted
the role of microparticles and exosomes in regenerative
processes [29]. In addition, microparticles from murine
embryonic stem cells have been shown capable of repro-
gramming hematopoietic progenitors through RNA trans-
fer [30]. Previous studies have already suggested that
microparticles play a part in coagulation, as these parti-
cles can express phosphatidylserine and bind active coag-
ulation factors [24]. Moreover, they express tissue factor,
which initiates the coagulation cascade [24,31]. Recent
studies from our laboratory demonstrated that extracellu-
lar vesicles produced by human liver-derived MSCs also
contain mRNA coding for FVIII (G. Rommelaere, S.
Eeckhoudt, C. Lombard, E. Sokal, unpublished data).
Future investigation is now required to demonstrate
whether infused MSCs could influence host cells, includ-
ing recipient liver endothelial cells, and promote their
secretion of FVIII through extracellular vesicle-mediated
horizontal transfer of FVIII mRNA.
What we have learned from mature liver cell
transplantation in humans?
Mature liver cell transplantation has been successfully
performed in a variety of inborn errors of metabolism
cases [32,33]. Mature hepatocytes are not considered
FVIII-producing cells and therefore not candidates for
treating hemophilia A [12,13]. Liver cell transplantation
has significantly increased our clinical experience and skill
in terms of using a portal vein approach for delivering
cells into the liver, via either the percutaneous route or an
implanted catheter system [23,34]. The liver is the ideal
organ for cell delivery and homing, given that the portal
system is a low-pressure, terminal circulation system.
Allogeneic liver cell transplantation in two siblings with
FVII deficiency induced a decrease in FVII requirement
to 20% of the pretreatment doses at 8–10 weeks post-
therapy [35]. The result was transient, however, and both
patients later required full liver transplantation, at 7 and
8 months following the liver cell transplantation, respec-
tively [35]. This constituted the first evidence that cell
transplantation in humans can correct clotting factor defi-
ciencies, although hepatocytes would probably not be a
suitable cell choice for hemophilia A for the aforemen-
tioned reasons. Clinical liver cell transplantation experi-
ments in various conditions have demonstrated that,
while it is feasible to mitigate the underlying metabolic
defect, the durability of response is limited to a maximum
of 12–18 months, and any cure of the disease is only par-
tial [17,32,33,36,37]. Partial activity or protein replace-
ment may, however, be sufficient to transform severe
disease into that with a mild phenotype. To overcome the
problem of liver donor shortages, it is thus feasible to use
liver cells from one metabolic patient to treat another suf-
fering from a different metabolic disease. This is known
as the ‘domino’ concept and is already exploited in ortho-
topic liver transplantation [38].
Despite these findings, hepatocyte technology has not
emerged as a widely applicable technique given the fol-
lowing obstacles to its use: the requirement of one liver
for only a few recipients, the limited durability, the poor
resistance of hepatocytes in surviving cryopreservation
and storage [39], the risk of pathogen transmission com-
parable to the risk in full-organ transplants, and the lack
of adequate infrastructure in most hospitals to enable cell
preparation for infusion.
MSCs in human clinical applications
The human clinical use of MSCs is based on the different
properties of these cells, including replacing a patient’s
deficient cells in the target tissue [40], promoting endoge-
nous tissue repair from the patient’s own pluripotent stem
cells [41], and providing immunomodulatory treatment in
conditions like graft versus host diseases or other immune-
related diseases [42]. When MSCs are used to treat genetic
disorders, they must be of allogeneic origin, while autolo-
gous cells can be used for tissue repair in acquired dis-
eases. In 2012, over 2000 patients underwent cell-based
therapies in Europe, half of which consisted of the trans-
plantation of MSCs primarily originating from the bone
marrow or adipose tissue [43]. The cells were autologous
in 60% of patients, who mostly suffered from rheumato-
logical, musculoskeletal, or cardiovascular disorders. Allo-
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geneic cells were primarily used in hematology–oncology
disorders. The MSCs transplanted in these cases were
obtained from the bone marrow or adipose tissue, yet
these cells can also be harvested from Wharton’s jelly in
the umbilical cord or from other tissues, including the liver
[19,44]. Adult human liver-derived MSCs can, when sub-
mitted to specific hepatocyte differentiation protocols,
acquire functional capacities, such as urea synthesis, biliru-
bin conjugation, de novo glucose synthesis, and cytochrome
P450 activities. These cells express and produce FVIII in
undifferentiated state, yet lose this capacity following hepa-
tocyte differentiation, thus providing further evidence of
the absence of FVIII expression by hepatocytes [12,13].
Adult human liver-derived MSCs have been demonstrated
capable of engrafting and repopulating rodent livers fol-
lowing infusion in the portal system [19,45].
Before exploring human applications of liver-derived
MSCs, preclinical safety studies demonstrated that these
cells in culture do not proliferate indefinitely, but reach
normal senescence. In culture conditions, they do not
express oncogenes, exhibit a normal shortening of telomer-
ase following culture passages, and do not induce tumors
when injected into immunodeficient mice [46]. In humans,
MSCs have proven safe in numerous different clinical
applications and have never been reported to cause malig-
nancies in humans in the numerous ongoing trials [43].
It was demonstrated that, in one patient, indium-
labeled liver-derived MSCs distribute uniformly and per-
sist in human liver tissue following portal infusion, with
no extra-hepatic distribution [47]. Liver-derived MSCs
were successfully administered in a young infant suffering
from urea cycle disease, and transplanted cells could be
identified in the liver 3 months following infusion in two
different biopsy samples [48].
A Louvain University spin-off biotech company, Prom-
ethera Biosciences, successfully completed phase I/II mul-
ticentre clinical trials using liver-derived MSCs under
European Medicine Agency (EMA) regulations, following
a Pediatric Investigation Plan. The trial included 20 pedi-
atric patients suffering from urea cycle disorder or Cri-
gler–Najjar syndrome. Safety and preliminary efficacy
data were presented at the International Society for
Inborn Errors of Metabolism (SSIEM) in 2014 [49]. The
patients had received cell quantities corresponding to
between 0.3 and 4% of their theoretical liver mass, that
is, 12.5–200 million cells per kg. The preliminary efficacy
data demonstrated improvement in urea synthesis in sev-
eral patients with urea cycle disorder, as assessed by the
measurement of C13 incorporation into the urea [49].
Other stem cells have now undergone full clinical devel-
opment planning. As an example, in 2014, the Committee
for Medicinal Products for Human Use (CHMP) at the
European Medicines Agency (EMA) recommended Holo-
clarR (Chiesi Farmaceutici, Parma, Italy), the first
advanced therapy medicinal product (ATMP) containing
ex vivo expanded human epithelial cells, for approval in
the European Union (EU). HoloclarR is a treatment for
moderate to severe limbal stem cell deficiency caused by
physical or chemical burns to the eyes in adults.
In conclusion, stem cell technology is an attractive
approach for treating congenital genetic diseases, such as
hemophilia. This concept has been proven valid for inher-
ited metabolic disorders, with hepatocyte transplantation
demonstrating that metabolic activities can be transferred
to recipients of allogeneic cells, and this approach is now
in clinical development using stem cell technology. This
technique ensures additional safety, as the stem cells are
produced in accordance with GMP under strict control.
Different types of stem cells can produce coagulation fac-
tors in culture conditions, including liver-derived MSCs.
When such cells are transplanted in vivo, the mechanism
of action can be related not only to the direct engraft-
ment of stem cells producing FVIII or FIX, but possibly
also via the transfer of genetic material incorporated into
extracellular vesicles and exosomes.
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